Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05188573Not ApplicableWithdrawn

EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients

Role: lead

NCT06803771Not ApplicableRecruiting

Surveillance of Pancreatic Health After Diabetes Diagnosis

Role: collaborator

NCT05188586Not ApplicableTerminated

New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

Role: lead

NCT03869814Unknown

Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

Role: lead

All 4 trials loaded